21 results
8-K
EX-99.1
UNCY
Unicycive Therapeutics Inc
14 Nov 23
Unicycive Announces Third Quarter 2023 Financial Results and Provides Business Update
4:42pm
development and corporate leadership experience. We also remain very active within the the medical community with a booth at Kidney Week and positive results … of Sara Kenkare-Mitra, PhD, adding decades of drug development and corporate leadership experience. Dr. Kenkare-Mitra brings Unicycive expertise spanning
8-K
EX-99.1
UNCY
Unicycive Therapeutics Inc
6 Sep 23
Unicycive Therapeutics Strengthens Board of Directors with Appointment of Sara Kenkare-Mitra, PhD
9:16am
believe Sara’s leadership and experience in drug development spanning more than 25 years will significantly help bolster Unicycive’s future growth … .
“We are thrilled to welcome Dr. Kenkare-Mitra to our Board of Directors and know that her extensive drug development and corporate leadership experience
PRE 14A
2lw7k
18 Apr 23
Preliminary proxy
5:25pm
DEF 14A
py1m0
19 Apr 22
Definitive proxy
4:00pm
10-K
x8e7xl hu1
31 Mar 22
Annual report
6:18am
10-Q
n3mulild29zdk7
16 Aug 21
Quarterly report
6:06am
424B4
y8z9h3gdo67tzomhia3
14 Jul 21
Prospectus supplement with pricing info
1:59pm
S-1/A
1fnfqs 28m37
7 Jun 21
IPO registration (amended)
7:01am
S-1
1fo6o 4p40
21 May 21
IPO registration
4:07pm
DRS/A
ddjee1 n6udj
29 Apr 21
Draft registration statement (amended)
12:00am
DRS/A
7olctx
18 Feb 21
Draft registration statement (amended)
12:00am
DRS/A
9gcztdxua0vvxc2nh5
2 Nov 20
Draft registration statement (amended)
12:00am